As we look ahead to the American Society of Hematology (ASH) Annual Meeting in 2025, the field feels more dynamic and forward-thinking than at any time in the last decade. ASH has always been the meeting where scientific breakthroughs meet clinical reality, but the breadth of innovation expected this year is particularly remarkable. The discussions emerging across cellular therapy, gene editing, aging biology and precision immunology reflect a discipline moving rapidly toward more personalised, curative and scalable treatments.
Here are the top six things I’m most excited to see at this year’s ASH conference:
1) Cellular immunotherapies 2.0
One of the most exciting areas continues to be next-generation cellular immunotherapies. While CAR-T therapy has transformed the treatment landscape for lymphomas and myeloma, the field is quickly expanding beyond its early foundations. Allogeneic, 'off-the-shelf' CAR-T constructs are now showing increasing clinical durability, while CAR-NK therapies are emerging as a potentially safer and more readily manufactured platform. Advances in synthetic biology are enabling multi-specific CAR designs capable of targeting several antigens at once, with the aim of overcoming relapse caused by antigen escape. These developments signal a shift from proof-of-concept immunotherapy to highly engineered, scalable immune platforms.
2) A new chapter of gene editing
Gene editing will also be a major focus at ASH 2025. Following the first regulatory approvals of CRISPR-based therapies, there is growing anticipation around the evolution of in vivo editing technologies, which may one day allow direct gene correction inside the body without the need for stem-cell harvest. At the same time, the move toward lower-intensity or even non-genotoxic conditioning is gathering pace, raising the possibility that curative therapies for haemoglobinopathies, bone-marrow failure syndromes and even rare leukemias could become more accessible. Long-term follow-up data on safety, durability, fertility and global access will be especially important themes this year.
3) Precision takes the lead in myeloid disease
For myeloid malignancies, 2025 may represent a turning point in precision-directed therapy. Menin inhibitors for KMT2A-rearranged and NPM1-mutated AML continue to generate encouraging results, and new FLT3 inhibitors aimed at overcoming known resistance patterns are moving through the pipeline. Therapies directed against TP53-mutant disease, including p53 reactivators and immunotherapeutic approaches, will be closely followed. The combined effect of these advances is a shift toward molecularly tailored treatment strategies guided by minimal residual disease and risk-adapted decision-making.
4) CHIP on the radar
One area I am personally watching with particular interest is clonal haematopoiesis (CHIP) and inflammation. This rapidly expanding field sits at the intersection of haematology, cardiovascular disease, immunology and aging biology. We are now seeing early interventional trials testing whether modulating inflammatory pathways can reduce disease risk in people with CHIP, while new data continue to clarify its links with dementia, chemotherapy toxicity and transplant outcomes. ASH 2025 will likely provide some of the clearest signals yet about whether CHIP may evolve from a biomarker into a modifiable condition.
5) Frontline breakthroughs in myeloma
In multiple myeloma, the therapeutic landscape continues to evolve at speed. Immunotherapy, once reserved for late-line treatment, is increasingly moving into the frontline setting. Real-world data comparing bispecific antibodies with CAR-T therapies are anticipated, alongside further insights into quadruplet regimens and new therapeutic targets such as GPRC5D and FcRH5. Trials exploring treatment cessation guided by minimal residual disease may also reshape how we think about long-term disease control and the possibility of functional cures.
6) Shifting scope: a multidisciplinary affair
Beyond individual disease areas, ASH 2025 will feature several keynote events that are likely to influence the broader scientific conversation. The Presidential Symposium will focus on the future of immune engineering, while the E. Donnall Thomas Lecture is expected to highlight curative frontiers in gene editing. The Ham-Wasserman Lecture will examine the role of inflammation and aging in haematologic disease, reflecting a growing recognition that immune dysregulation and vascular biology underpin many of the conditions we treat. The Late-Breaking Abstracts session, always a highlight of the meeting, will undoubtedly showcase practice-changing clinical trial results that will shape therapeutic standards in the years ahead.
Finally, several emerging themes will cut across disciplines. The integration of artificial intelligence into pathology, flow cytometry and clinical prediction models continues to accelerate. Novel therapeutic insights are also emerging in rare diseases, the microbiome–haematology interface and global access to advanced therapies. These conversations reflect a shift toward a more interconnected and equitable vision for the future of haematology.
Overall, ASH 2025 promises to be a landmark meeting, one that not only reveals where the science stands today but also offers a glimpse into the therapeutic possibilities of tomorrow. I look forward to engaging with colleagues across the global community and following the discoveries that will undoubtedly shape how we diagnose, treat and ultimately prevent haematologic disease.
If you will be attending ASH this year, either virtually or in person, I would welcome the chance to connect.
By Dr Azhaar Ashraf
